{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:26:26Z","timestamp":1761567986486,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cpet.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:10:59Z","timestamp":1704816659000},"page":"249-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positron Emission Tomography\/Computed Tomography Transformation of Oncology"],"prefix":"10.1016","volume":"19","author":[{"given":"Salikh","family":"Murtazaliev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Sheikhbahaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja B.","family":"S\u00f3lnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.cpet.2023.12.010_bib1","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib2","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into the future","volume":"105","author":"Gulla\u2019","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.010_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.010_bib7","first-page":"487","article-title":"Multiple myeloma: pathophysiology and progress in management","volume":"58","author":"Kuroda","year":"2017","journal-title":"Jpn J Clin Hematol"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3390\/ijms22126208","article-title":"Myeloma bone disease: a comprehensive review","volume":"22","author":"Mukkamalla","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.rct.0000237820.41549.c9","article-title":"Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography","volume":"31","author":"Hur","year":"2007","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A\u00a0prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.010_bib12","first-page":"427","article-title":"Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma","volume":"49","author":"Hur","year":"2008","journal-title":"Acta Radiol Stockh Swed 1987"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnumed.107.045641","article-title":"18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma","volume":"49","author":"Fonti","year":"2008","journal-title":"J\u00a0Nucl Med Off Publ Soc Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.010_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis","volume":"218","author":"Rama","year":"2022","journal-title":"Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.cpet.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.cpet.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","article-title":"18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System","volume":"46","author":"Jung","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"31","author":"Han","year":"2021","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","article-title":"The prognostic significance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.010_bib25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V73.1.20.20","article-title":"Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft","volume":"73","author":"Fermand","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.010_bib27","first-page":"149","article-title":"Allogeneic bone marrow transplantation in the treatment of hematologic diseases","volume":"4","author":"Yee","year":"1985","journal-title":"Clin Pharm"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.010_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.010_bib30","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.010_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.010_bib32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s00259-018-3997-0","article-title":"Prognostic value of [18F]FDG-PET\/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation","volume":"45","author":"Stolzenburg","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"19","key":"10.1016\/j.cpet.2023.12.010_bib33","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.cpet.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.cpet.2023.12.010_bib35","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.010_bib36","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A\u00a0phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.010_bib37","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.cpet.2023.12.010_bib38","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.010_bib39","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-011-1993-8","article-title":"18F-FDG PET\/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation","volume":"39","author":"Derlin","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.010_bib41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2967\/jnumed.111.098830","article-title":"Imaging of multiple myeloma and related plasma cell dyscrasias","volume":"53","author":"Walker","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.010_bib42","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.cpet.2023.12.010_bib43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cpet.2023.12.010_bib45","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.010_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.010_bib47","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ejh.12907","article-title":"Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register","volume":"99","author":"Nahi","year":"2017","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.010_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23201","article-title":"Trends and outcomes of modern staging of solitary plasmacytoma of bone","volume":"87","author":"Warsame","year":"2012","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.010_bib51","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.cpet.2023.12.010_bib52","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","article-title":"Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.010_bib53","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.leukres.2013.06.002","article-title":"CXCR4 is a good survival prognostic indicator in multiple myeloma patients","volume":"37","author":"Bao","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.cpet.2023.12.010_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"issue":"23","key":"10.1016\/j.cpet.2023.12.010_bib55","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.3390\/cancers13235920","article-title":"In\u00a0Vivo targeting of CXCR4-new horizons","volume":"13","author":"Schottelius","year":"2021","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2023.12.010_bib56","doi-asserted-by":"crossref","first-page":"A81","DOI":"10.1186\/2197-7364-1-S1-A81","article-title":"New imaging agents targeting chemokine receptor CXCR4 for PET\/SPECT and MRI","volume":"1","author":"Poty","year":"2014","journal-title":"EJNMMI Phys"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.010_bib57","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1136","key":"10.1016\/j.cpet.2023.12.010_bib58","doi-asserted-by":"crossref","first-page":"20211272","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT: comparison with 18F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.010_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.010_bib60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.010_bib61","first-page":"754","article-title":"Biokinetics and dosimetry of 177Lu-pentixather","volume":"63","author":"H\u00e4nscheid","year":"2022","journal-title":"J\u00a0Nucl Med Off Publ Soc Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.010_bib62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J\u00a0Nucl Med Off Publ Soc Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.010_bib63","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.010_bib64","first-page":"815","article-title":"[Evaluation of the effects of thymopentin on the incidence of leucopenia in patients treated with chemotherapy for breast carcinoma]","volume":"81","author":"Cartia","year":"1990","journal-title":"Minerva Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:11:49Z","timestamp":1761563509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859823001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1556859823001037"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.010","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron Emission Tomography\/Computed Tomography Transformation of Oncology","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}